Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

[1]  H. Leufkens,et al.  Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. , 2011, Bulletin of the World Health Organization.

[2]  S. Yusuf,et al.  The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. , 2010, Circulation.

[3]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[4]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[5]  W. Brouwer,et al.  Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World , 2010, PLoS medicine.

[6]  S. Yusuf,et al.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.

[7]  M. V. van Mourik,et al.  Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data , 2010, BMC cardiovascular disorders.

[8]  Salim Yusuf,et al.  The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. , 2009, American heart journal.

[9]  M. Inoue,et al.  Self-reported stroke and myocardial infarction had adequate sensitivity in a population-based prospective study JPHC (Japan Public Health Center)-based Prospective Study. , 2009, Journal of clinical epidemiology.

[10]  S. Yusuf,et al.  Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial , 2009, The Lancet.

[11]  Alan D. Lopez,et al.  Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India , 2009, Circulation.

[12]  K. Kotseva,et al.  Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries , 2009, The Lancet.

[13]  S. Yusuf,et al.  Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data , 2008, The Lancet.

[14]  R. John.  Crowding out effect of tobacco expenditure and its implications on household resource allocation in India. , 2008, Social science & medicine.

[15]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[16]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[17]  K. Furie,et al.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the , 2006, Circulation.

[18]  S. Yusuf,et al.  WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). , 2005, Bulletin of the World Health Organization.

[19]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[20]  C. Kooperberg,et al.  Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. , 2004, American journal of epidemiology.

[21]  Douglas W Mahoney,et al.  Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. , 2004, Journal of clinical epidemiology.

[22]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[23]  N J Wald,et al.  A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.

[24]  S. Yusuf.  Two decades of progress in preventing vascular disease , 2002, The Lancet.

[25]  S. Kegeles,et al.  What is community? An evidence-based definition for participatory public health. , 2001, American journal of public health.

[26]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[27]  J. Pogue,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[28]  M M Bergmann,et al.  Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. , 1998, American journal of epidemiology.

[29]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[30]  B Healy,et al.  The Yentl syndrome. , 1991, The New England journal of medicine.

[31]  Santhosh K. P. Kumar,et al.  Water supplementation in exclusively breastfed infants during summer in the tropics , 1991, The Lancet.

[32]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[33]  N. Wald.  A strategy to reduce cardiovascular disease by more than 80 , 2012 .

[34]  Haynes Rb,et al.  Interventions for enhancing medication adherence (Review) , 2008 .

[35]  F. Ramsey,et al.  The statistical sleuth : a course in methods of data analysis , 2002 .

[36]  F. Lampe,et al.  Validity of a self-reported history of doctor-diagnosed angina. , 1999, Journal of clinical epidemiology.